Clinical trials: Free Radicals
Ischemic Stroke
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- RODIN (NCT05041010)
- Testing
- Neu2000KWL group
- Where
- 24 sites in South Korea
- Volunteers
- 496 people
- Sponsor
- GNT Pharma
Alzheimer Disease
ASURE: Alzheimer Study Using oRal Edaravone
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study in patients with Alzheimer's Disease (AD).
- Trial name
- NCT05323812
- Testing
- TW001
- Where
- 6 sites in Croatia, Netherlands
- Volunteers
- 61 people
- Sponsor
- Treeway B.V.
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional…
- Trial name
- NCT00415519
- Testing
- MCI-186
- Volunteers
- 25 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24…
- Trial name
- NCT00330681
- Testing
- MCI-186
- Volunteers
- 206 people
- Sponsor
- Shionogi
Dyspepsia, Chronic Gastritis
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
To study the anti free radical \& inflammatory effect and safety of Rebamipide in patients suffering of dyspepsia due to chronic gastritis.
- Trial name
- NCT00996788
- Testing
- Rebamipide
- Where
- Indonesia
- Volunteers
- 55 people
- Sponsor
- PT Otsuka Indonesia
Healthy Volunteers, Healthy
A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers
The study will be a double-blind, randomized, crossover, single-dose assessment of IV-administered GC4711 compared to GC4419 in healthy volunteers.
- Trial name
- NCT03194139
- Testing
- GC4711 30 mg IV, GC4711 50 mg IV, GC4419 45 mg IV
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Ischemic Stroke
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- SONIC (NCT02831088)
- Testing
- Neu2000KWL High-does group, Neu2000KWL Low-does group
- Where
- 6 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- GNT Pharma
Cardiac Arrest
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
This study aims to investigate the efficacy and safety of Neu2000KWL, a neuroprotectant, in patients resuscitated from out-of-hospital cardiac arrest and receiving therapeutic hypothermia.
- Trial name
- AWAKE (NCT03651557)
- Testing
- Neu2000KWL High-dose group, Neu2000KWL Low-dose group
- Where
- 6 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- GNT Pharma
Healthy Volunteers, Healthy
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
This is a partially double-blind study in healthy adult subjects, which will be conducted as a placebo- and active-controlled, single-dose, crossover study.
- Trial name
- NCT03164109
- Testing
- GC4419 IV, Oral moxifloxacin
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.